Clomipramine-Induced Urinary Retention in an Adult Male - A Case Report.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY Current drug safety Pub Date : 2025-01-28 DOI:10.2174/0115748863337946250101110356
Priya Mehta, Pooja Sapovadia, Bhargav Purohit
{"title":"Clomipramine-Induced Urinary Retention in an Adult Male - A Case Report.","authors":"Priya Mehta, Pooja Sapovadia, Bhargav Purohit","doi":"10.2174/0115748863337946250101110356","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Clomipramine, a Tricyclic Antidepressant (TCA), is known for its efficacy in treating Obsessive-compulsive Disorder (OCD). However, it is associated with several side effects, including urinary retention. This case report discusses the case of a 20-year-old male with OCD who developed urinary retention following clomipramine administration.</p><p><strong>Case representation: </strong>A 20-year-old male with a one-year history of OCD with psychotic features was admitted to SIR-T Hospital, Bhavnagar, due to worsening symptoms. He was prescribed clomipramine along with other psychotropic medications. On the 16th day of hospitalization, the patient experienced acute urinary retention, necessitating catheterization. Clomipramine dosage was subsequently reduced, resulting in the resolution of urinary retention. The patient was discharged after 29 days with no further urinary complications.</p><p><strong>Discussion: </strong>The causality assessment suggested a probable link between clomipramine and urinary retention, supported by the Naranjo Scale, WHO-UMC criteria, and literature. The anticholinergic properties of clomipramine likely contributed to the condition. Despite its side effects, clomipramine remains a valuable treatment for OCD, requiring careful dose management to mitigate adverse effects.</p><p><strong>Conclusion: </strong>Clinicians should be vigilant for urinary retention in patients receiving clomipramine, especially at higher doses. Regular monitoring and dose adjustments are crucial for managing this side effect without compromising the therapeutic benefits for OCD.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863337946250101110356","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Clomipramine, a Tricyclic Antidepressant (TCA), is known for its efficacy in treating Obsessive-compulsive Disorder (OCD). However, it is associated with several side effects, including urinary retention. This case report discusses the case of a 20-year-old male with OCD who developed urinary retention following clomipramine administration.

Case representation: A 20-year-old male with a one-year history of OCD with psychotic features was admitted to SIR-T Hospital, Bhavnagar, due to worsening symptoms. He was prescribed clomipramine along with other psychotropic medications. On the 16th day of hospitalization, the patient experienced acute urinary retention, necessitating catheterization. Clomipramine dosage was subsequently reduced, resulting in the resolution of urinary retention. The patient was discharged after 29 days with no further urinary complications.

Discussion: The causality assessment suggested a probable link between clomipramine and urinary retention, supported by the Naranjo Scale, WHO-UMC criteria, and literature. The anticholinergic properties of clomipramine likely contributed to the condition. Despite its side effects, clomipramine remains a valuable treatment for OCD, requiring careful dose management to mitigate adverse effects.

Conclusion: Clinicians should be vigilant for urinary retention in patients receiving clomipramine, especially at higher doses. Regular monitoring and dose adjustments are crucial for managing this side effect without compromising the therapeutic benefits for OCD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Current drug safety
Current drug safety PHARMACOLOGY & PHARMACY-
CiteScore
2.10
自引率
0.00%
发文量
112
期刊介绍: Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
期刊最新文献
Comprehensive Review of Gestational Diabetes: Pathophysiology, Pharmacological Management and the Role of Pharmaceutical Care. Rhabdomyolysis Following Trimethoprim-Sulfamethoxazole Therapy: A Case Report and Review of the Literature. Clomipramine-Induced Urinary Retention in an Adult Male - A Case Report. Reported Postoperative Surgical Site Infections in Tertiary Care Hospitals, Systematic Review of Recent Literature. A Rare Case of Fatal Toxic Epidermal Necrolysis (TEN) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome in a Patient with Rheumatoid Arthritis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1